Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.40

0.0%

Nov 28 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spekulatius who wrote (865)	3/26/2001 3:01:12 PM
From: Mark Bong	of 1475

The burn rate will be increased. But the estimated cost to develop and commercialize the first Eligix product is only $4.0 MM, so there is some hope that revenues will begin later this year that will offset the cash burn. The LTD of $22MM is ELIGIX preferred stock. The value of this is included in the purchase price, so there is no dilution here, as for as I can see. Eligix will make best efforts to convert all of the preferred into common prior to the closing of this transaction, and if they don't then certain formula adjustments are made part of the transaction to keep the cost level at 6.6MM exchange shares to BTRN. IMHO, long term debt is not an issue here, but of course cash burn is a big issue. If BTRN is correct about this technology, they this will be a beneficial deal. If not, then BTRN is in big trouble.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next